Genexine Inc (095700) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.011x

Based on the latest financial reports, Genexine Inc (095700) has a cash flow conversion efficiency ratio of -0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.97 Billion ≈ $-2.02 Million USD) by net assets (₩260.01 Billion ≈ $176.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Genexine Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Genexine Inc - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Genexine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Genexine Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genexine Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Anfield Energy Inc. NASDAQ:AEC	-0.070x
OM INFRA LIMITED NSE:OMINFRAL	-0.051x
Sao Ta Foods JSC VN:FMC	0.089x
Casino Guichard Perrachon SA PA:CO	0.071x
Viet Nam Power Development JSC VN:VPD	N/A
Kino Indonesia Tbk PT JK:KINO	0.101x
First US Bancshares Inc NASDAQ:FUSB	0.039x
Fast Ejendom CO:FED	0.010x

Annual Cash Flow Conversion Efficiency for Genexine Inc (2009–2024)

The table below shows the annual cash flow conversion efficiency of Genexine Inc from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Genexine Inc stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩261.68 Billion ≈ $177.34 Million	₩-1.65 Billion ≈ $-1.12 Million	-0.006x	+95.09%
2023-12-31	₩296.90 Billion ≈ $201.21 Million	₩-38.05 Billion ≈ $-25.79 Million	-0.128x	+11.07%
2022-12-31	₩276.15 Billion ≈ $187.15 Million	₩-39.80 Billion ≈ $-26.97 Million	-0.144x	-485.45%
2021-12-31	₩517.74 Billion ≈ $350.87 Million	₩-12.75 Billion ≈ $-8.64 Million	-0.025x	+41.89%
2020-12-31	₩535.60 Billion ≈ $362.97 Million	₩-22.69 Billion ≈ $-15.38 Million	-0.042x	+69.74%
2019-12-31	₩296.91 Billion ≈ $201.21 Million	₩-41.57 Billion ≈ $-28.17 Million	-0.140x	-123.77%
2018-12-31	₩320.51 Billion ≈ $217.20 Million	₩-20.05 Billion ≈ $-13.59 Million	-0.063x	+72.70%
2017-12-31	₩113.91 Billion ≈ $77.19 Million	₩-26.10 Billion ≈ $-17.69 Million	-0.229x	-176.72%
2016-12-31	₩170.24 Billion ≈ $115.37 Million	₩-14.10 Billion ≈ $-9.55 Million	-0.083x	-534.09%
2015-12-31	₩125.77 Billion ≈ $85.23 Million	₩-1.64 Billion ≈ $-1.11 Million	-0.013x	-135.88%
2012-12-31	₩45.83 Billion ≈ $31.06 Million	₩1.67 Billion ≈ $1.13 Million	0.036x	+125.17%
2011-12-31	₩24.04 Billion ≈ $16.29 Million	₩-3.48 Billion ≈ $-2.36 Million	-0.145x	+17.18%
2010-12-31	₩26.43 Billion ≈ $17.91 Million	₩-4.62 Billion ≈ $-3.13 Million	-0.175x	-19184.88%
2009-12-31	₩38.50 Billion ≈ $26.09 Million	₩35.23 Million ≈ $23.87K	0.001x	--

About Genexine Inc

KQ:095700 Korea Biotechnology

Market Cap

$88.92 Million

₩131.21 Billion KRW

Market Cap Rank

#19741 Global

#1016 in Korea

Share Price

₩2885.00

Change (1 day)

-9.70%

52-Week Range

₩2840.00 - ₩7100.00

All Time High

₩131402.78